Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
Abstract Background Esophageal neuroendocrine carcinoma (NEC) is a rare cancer with an extremely poor prognosis. The average overall survival of patients with metastatic disease is only 1 year. The efficacy of anti‐angiogenic agents combined with immune checkpoint inhibitors remains unknown. Case Pr...
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Wiley
2023-09-01
|
| سلاسل: | Cancer Reports |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1002/cnr2.1855 |